William Blair research analyst Myles Minter’s note on the swift FDA approval of Alzheimer’s drug Leqembi was cited in MedCity News.
Equity Research
Myles Minter Quoted in MedCity News
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
Inari Medical, Inc.: Initiation of Research Coverage
William Blair initiated research coverage of Inari Medical, Inc. (NARI $54.73), a medical device company that develops interventional products for patients suffering from venous diseases.
Read moreGifting Appreciated Securities to a Donor-Advised Fund Program
This charitable vehicle provides a simplified approach that allows you to maximize your charitable donations and tax benefits—an approach that can transform the way you give.
Read moreClio Valued at $3B in $900M Series F Investment Led by NEA
William Blair acted as the exclusive financial advisor to Clio in connection with its $900 million Series F investment round led by New Enterprise Associates, at a $3.0 billion valuation.
Read more